arrow
C

Camillo Porta

aou consorziale policlinico di bari
H指数:79
被引数:5.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

34 Belzutifan联合仑伐替尼与卡博替尼在PD-(L)1后肾细胞癌中的比较:LITESPARK-011 III期研究中健康相关生活质量结局

2026-09-020
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study

卡博替尼和替莫唑胺在晚期进展性神经内分泌肿瘤患者中的应用:一项II期研究

2026-04-100
OAAI
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial☆

纳武利尤单抗联合伊匹木单抗与舒尼替尼用于晚期肾细胞癌一线治疗的疗效和安全性:III期CheckMate 214试验的最终分析

2026-03-030
OAAI
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

在接受基于免疫治疗的一线治疗后转移性肾细胞癌(mRCC)中的患者流失率:来自国际mRCC数据库联盟(IMDC)的结果

2026-01-010
PRE
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

肾细胞癌辅助性帕博利珠单抗的实证据:多中心真实世界ARON-1研究的结果

2025-11-140
OAAI
Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors

肾细胞癌患者接受免疫检查点抑制剂治疗后发生内分泌学免疫相关不良事件的风险因素

2025-11-100
OAAI
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

与毒性相关的免疫治疗停药及结局:接受基于免疫联合治疗方案的晚期肾细胞癌患者(ARON-1研究)

2025-11-040
PRE
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients

纵向验证PROFFIT问卷以评估癌症患者的财务毒性

2025-10-010
OAAI
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

来自随机III期CheckMate 9ER试验的尼鲁单抗联合卡博赞替尼治疗晚期肾细胞癌的最终分析

2025-09-230
OAAI
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study

肾细胞癌辅助免疫治疗和复发管理的现状:欧洲德尔菲研究的见解

2025-06-070
PRE
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

帕博利珠单抗联合仑伐替尼在转移性肾细胞癌患者中的应用:国际ARON-1研究的真实世界证据

2025-05-090
OA